Replies to post #122027 on Biotech Values

[10nisman]

Ernst & Young Entrepreneur Award is B.S

Obviously. It's a great way for E&Y to reward certain clients for paying their audit/tax fees on time.

I am not saying wheeler is like that...But since he became CEO in 2006, not a lot has happened from business standpoint(besides lovenox which is huge)...Of course internally they are continuing to make progress on copaxone and building IP for FOB. That's why I said, the FOB partnership is a real test for wheeler I think he will deliver for shareholders

Not a lot has happened? Ridiculous comment.

[DewDiligence]

Ernst & Young Entrepreneur Award is B.S.

You realized that my comments in #msg-64466820 were facetious, right?

[mcbio]

Wheeler should be rated based on how he delivers to shareholders.

I strongly disagree with this notion. Wheeler can't control how the market reacts to his and MNTA's accomplishments. How can he control the the market's reaction to the perceived Teva threat with generic Lovenox and whether or not the market views MNTA's own success with generic Lovenox as validation for its platform (I'd argue it hasn't)? Wheeler has delivered as far as I am concerned. Now it's just a question to me of at what point will the market give MNTA more credit for its existing accomplishments to date and its potential prospects to come. I'm content to continue to hold MNTA until I feel we've reached that point. Perhaps it will take success on the generic Copaxone front or the FoB front, but I am willing to hold.